Paper39963129
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.
Moser LM and 16 others. Front Immunol, 2025. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. Papers, record 39963129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39963129
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Rhabdomyosarcoma | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Cytokine-Induced Killer Cells | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Cell Line, Tumor | |
| Xenograft Model Antitumor Assays | |
| Cytotoxicity, Immunologic | |
| Cytokines | |
| Female |
Source PubMed
References74
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32484595 | Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. | J Cell Physiol | 2020 | https://conductscience.org/library/papers/32484595 | PubMed |
| 2 | 16997856 | Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. | J Leukoc Biol | 2006 | https://conductscience.org/library/papers/16997856 | PubMed |
| 3 | 37148198 | Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. | Neuro Oncol | 2023 | https://conductscience.org/library/papers/37148198 | PubMed |
| 4 | 23985696 | Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". | Mol Ther | 2013 | https://conductscience.org/library/papers/23985696 | PubMed |
| 5 | 34686489 | CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1. | Cancer Immunol Res | 2021 | https://conductscience.org/library/papers/34686489 | PubMed |
| 6 | 19375652 | Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. | Exp Hematol | 2009 | https://conductscience.org/library/papers/19375652 | PubMed |
| 7 | 36529024 | A2AR limits IL-15-induced generation of CD39+ NK cells with high cytotoxicity. | Int Immunopharmacol | 2023 | https://conductscience.org/library/papers/36529024 | PubMed |
| 8 | 35879429 | Natural killer cells in antitumour adoptive cell immunotherapy. | Nat Rev Cancer | 2022 | https://conductscience.org/library/papers/35879429 | PubMed |
| 9 | 36634289 | CAR T-Cells for Cure in Pediatric B-ALL. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36634289 | PubMed |
| 10 | 11342413 | Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. | Blood | 2001 | https://conductscience.org/library/papers/11342413 | PubMed |
| 11 | 37481241 | INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia. | Transplant Cell Ther | 2023 | https://conductscience.org/library/papers/37481241 | PubMed |
| 12 | 29769722 | Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. | Nature | 2018 | https://conductscience.org/library/papers/29769722 | PubMed |
| 13 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 14 | 22116087 | The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. | Nat Rev Immunol | 2011 | https://conductscience.org/library/papers/22116087 | PubMed |
| 15 | 29029499 | Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. | Oncotarget | 2017 | https://conductscience.org/library/papers/29029499 | PubMed |
| 16 | 31900462 | 'Off-the-shelf' allogeneic CAR T cells: development and challenges. | Nat Rev Drug Discov | 2020 | https://conductscience.org/library/papers/31900462 | PubMed |
| 17 | 26768688 | Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. | Haematologica | 2016 | https://conductscience.org/library/papers/26768688 | PubMed |
| 18 | 18565854 | In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. | Blood | 2008 | https://conductscience.org/library/papers/18565854 | PubMed |
| 19 | 33603738 | Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ γδT Cells a Unique Lymphocyte Subset. | Front Immunol | 2020 | https://conductscience.org/library/papers/33603738 | PubMed |
| 20 | 32483603 | Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. | Blood | 2020 | https://conductscience.org/library/papers/32483603 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42613325 | Role of epithelial-mesenchymal transition (EMT) in malignancies: current status and future prospects. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42613325 | PubMed |
| 42527917 | Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42527917 | PubMed |
| 41941697 | First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/41941697 | PubMed |
| 41394804 | Current landscape of CAR-therapy for osteosarcoma and rhabdomyosarcoma. | Front Immunol | 2025 | https://conductscience.org/library/papers/41394804 | PubMed |
| 41340123 | Implications of DNA damage response and immunotherapy in tumor therapy. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/41340123 | PubMed |
| 41112277 | Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival. | Front Immunol | 2025 | https://conductscience.org/library/papers/41112277 | PubMed |
| 41038289 | Towards directed therapy for fusion-positive rhabdomyosarcoma. | Pharmacol Ther | 2025 | https://conductscience.org/library/papers/41038289 | PubMed |
| 41007114 | Tumor-Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies. | Children (Basel) | 2025 | https://conductscience.org/library/papers/41007114 | PubMed |
| 40944718 | Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/40944718 | PubMed |
| 40758198 | Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40758198 | PubMed |
| 40575784 | Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40575784 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD247 | 919 | PubTator's text mining | https://conductscience.org/library/genes/919 | NCBI Gene |
| CD28 | 940 | PubTator's text mining | https://conductscience.org/library/genes/940 | NCBI Gene |
| CXADRP1 | 653108 | PubTator's text mining | https://conductscience.org/library/genes/653108 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| GNLY | 10578 | PubTator's text mining | https://conductscience.org/library/genes/10578 | NCBI Gene |
| HLA-C | 3107 | PubTator's text mining | https://conductscience.org/library/genes/3107 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL10 | 3586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| IL4 | 3565 | PubTator's text mining | https://conductscience.org/library/genes/3565 | NCBI Gene |
| NCAM1 | 4684 | PubTator's text mining | https://conductscience.org/library/genes/4684 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39963129
GET https://conductscience.org/api/papers/v1/39963129/references?page=2